ENvue Medical, Inc. (NASDAQ: FEED)

NanoVibronix, Inc. develops, manufactures, and markets noninvasive ultrasound based products for biofilm prevention, pain therapy, and wound healing as well as enteral feeding systems for hospital patients. The company operates through two wholly owned subsidiaries: NanoVibronix Ltd. which does business as Nano OpCo and Envizion Holdings LLC which does business as Envizion. Nano OpCo concentrates on devices that use low frequency ultrasound to prevent bacterial biofilm on catheters to relieve pain and to promote wound healing. Envizion focuses on a system that guides the placement of feeding tubes to improve safety and efficiency in enteral nutrition delivery.

The company generates revenue primarily from the sale of its ultrasound based devices such as UroShield, PainShield, and WoundShield and from the sale of its Envizion System and related disposable feeding tubes. Revenue also comes from recurring purchases of disposable components like transducers and patches and from distribution agreements with partners in various geographic markets. Nano OpCo sells its devices directly to consumers and through distributors in Europe, Asia, and the Middle East while Envizion sells its system mainly to hospitals in the United States. The disposable nature of the transducers and patches creates a steady aftermarket stream of income for Nano OpCo.

The company operates through the following segments.

• Nano OpCo: This segment develops and markets noninvasive ultrasound based devices including UroShield for urinary catheter biofilm prevention, PainShield for pain relief and wound healing, and WoundShield for wound care. UroShield is designed to be clipped onto urinary catheters to deliver ultrasound energy that reduces bacterial colonization and discomfort. PainShield uses a patch that adheres to the skin to deliver therapeutic ultrasound for conditions such as tendonitis and joint contractures. WoundShield applies a similar patch to wounds to stimulate tissue repair and increase oxygen flow. Revenue is generated from device sales and from recurring purchases of disposable transducers and patches.

• Envizion: This segment focuses on the Envizion System which assists in the placement of feeding tubes for enteral nutrition in hospital patients. The system includes a reusable base unit with an electromagnetic field generator and a disposable feeding tube that contains a passive sensor. The device provides real time tracking of the tube's position to avoid misplacement into the lungs. Revenue comes from system sales and from the sale of disposable feeding tubes designed for use with the system.

In the ultrasound based device market Nano OpCo competes with manufacturers of antibiotic coated and silver coated catheters for UroShield with traditional ultrasound therapy devices for PainShield and with advanced wound care companies such as 3M, Smith & Nephew, and Convatec for WoundShield. The Envizion System faces competition from the IRIS Kangaroo feeding tube and the Cortrak 2 Enteral Access System. NanoVibronix maintains a competitive edge through its proprietary surface acoustic wave technology, its portfolio of patents, and its ability to offer products that can be used in home settings without clinician supervision. The company holds numerous patents covering its ultrasound transduction methods and its trademark portfolio includes the names PainShield, UroShield, WoundShield, and Envizion in major markets. These intellectual property assets help protect its innovations and support licensing opportunities.

NanoVibronix serves a diverse customer base that includes distributors in the United Kingdom, Australia, New Zealand, and Malta as well as institutional buyers such as NHS Supply Chain in the UK. The company also lists Ultra Pain Products Inc as a major customer representing approximately 40% of total revenues. Additional customers include regional distributors in Europe and Asia that purchase Nano OpCo products for resale to pharmacies and clinics. For the Envizion segment customers are primarily hospitals in the United States that purchase the system, and disposable feeding tubes for inpatient care. Envizion has also signed agreements with select group purchasing organizations to expand its reach within the US hospital market.